ES2043716T3 - Formas de administracion oral con liberacion retardada. - Google Patents

Formas de administracion oral con liberacion retardada.

Info

Publication number
ES2043716T3
ES2043716T3 ES88107021T ES88107021T ES2043716T3 ES 2043716 T3 ES2043716 T3 ES 2043716T3 ES 88107021 T ES88107021 T ES 88107021T ES 88107021 T ES88107021 T ES 88107021T ES 2043716 T3 ES2043716 T3 ES 2043716T3
Authority
ES
Spain
Prior art keywords
delayed release
oral administration
forms
carbamazepine
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88107021T
Other languages
English (en)
Inventor
Satish Chandra Dr Khanna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of ES2043716T3 publication Critical patent/ES2043716T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

EL OBJETO DE LA PRESENTE INVENCION SON FORMAS DE ADMINISTRACION ORAL MEJORADAS, P.E. JARABES, CON LIBERACION RETARDADA DE CARBAMAZEPINA. LA LIBERACION RETARDADA DE CARBAMAZEPINA SE CONSIGUE MEDIANTE LA ELABORACION DE UNA FORMA CRISTALINA CUBICA DE TAMAÑO ADECUADO DE LOS CRISTALES DE DIHIDRATO CONTENIDOS EN LA FORMA DE ADMINISTRACION.
ES88107021T 1987-05-04 1988-05-02 Formas de administracion oral con liberacion retardada. Expired - Lifetime ES2043716T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH168287 1987-05-04

Publications (1)

Publication Number Publication Date
ES2043716T3 true ES2043716T3 (es) 1994-01-01

Family

ID=4216129

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88107021T Expired - Lifetime ES2043716T3 (es) 1987-05-04 1988-05-02 Formas de administracion oral con liberacion retardada.

Country Status (21)

Country Link
US (1) US5122543A (es)
EP (1) EP0289977B1 (es)
JP (1) JPH01131117A (es)
KR (1) KR960006059B1 (es)
AT (1) ATE94390T1 (es)
AU (1) AU619178B2 (es)
CA (1) CA1328219C (es)
DD (1) DD269784A5 (es)
DE (1) DE3884044D1 (es)
DK (1) DK169608B1 (es)
ES (1) ES2043716T3 (es)
FI (1) FI882044A7 (es)
HU (1) HU199074B (es)
IE (1) IE63081B1 (es)
IL (1) IL86211A (es)
MX (1) MX11339A (es)
NO (1) NO881933L (es)
NZ (1) NZ224476A (es)
PH (1) PH24895A (es)
PT (1) PT87381B (es)
ZA (1) ZA883135B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE4210711A1 (de) * 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
DE4422881A1 (de) * 1993-10-25 1995-04-27 Bayer Ag Kolloidal dispergierbare Wirkstoff-Formulierungen
EP0788346B9 (en) * 1994-03-18 2007-02-14 Supernus Pharmaceuticals, Inc. Emulsified drug delivery systems
DE4423078B4 (de) * 1994-07-01 2005-01-13 Awd.Pharma Gmbh & Co. Kg Verfahren zur Herstellung einer Carbamazepin-Arzneiform mit verzögerter Wirkstofffreisetzung
IL136807A0 (en) * 1997-12-19 2001-06-14 Taro Pharmaceuticals Usa Inc Topical carbamazepine formulation and methods of use
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
NZ526608A (en) * 2000-12-22 2006-06-30 Baxter Int Method for preparing submicron particle suspensions
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
IN190699B (es) 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
BR0212833A (pt) * 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
WO2003075830A2 (en) * 2002-03-14 2003-09-18 Sun Pharmaceutical Industries Limited Oral controlled drug delivery system containing carbamazepine
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
WO2006138202A2 (en) * 2005-06-14 2006-12-28 Baxter International Inc. Pharmaceutical formulations for minimizing drug-drug interactions
US20070134341A1 (en) * 2005-11-15 2007-06-14 Kipp James E Compositions of lipoxygenase inhibitors
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US9394327B1 (en) * 2013-03-15 2016-07-19 The Trustees Of California State University Nucleoside crystals, crystal nucleation and growth control with antifreeze proteins
JP2017537881A (ja) * 2014-11-18 2017-12-21 ピクサーバイオ コーポレーション 急性、術後、または慢性疼痛を治療する組成物およびその使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
US4213963A (en) * 1978-12-14 1980-07-22 Janssen Pharmaceutica N.V. Fluspirilene-containing compositions
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
JPS59147374A (ja) * 1983-02-10 1984-08-23 Fuji Xerox Co Ltd 電子写真複写機のブラシクリ−ニング方法
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
ATE78404T1 (de) * 1985-05-02 1992-08-15 Ciba Geigy Ag Hydrogele mit erhoehter beladungskapazitaet bezueglich einer in einem organischen loesungsmittel loeslichen wirksubstanz, deren herstellung sowie deren verwendung.
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
JPH0641286B2 (ja) * 1987-05-14 1994-06-01 信行 西井 自動包装装置
US4964606A (en) * 1989-10-26 1990-10-23 Ncr Corporation Overhead mount for a CRT

Also Published As

Publication number Publication date
IE881328L (en) 1988-11-04
DK238888D0 (da) 1988-05-03
JPH01131117A (ja) 1989-05-24
NZ224476A (en) 1990-09-26
NO881933D0 (no) 1988-05-03
ZA883135B (en) 1988-11-07
AU619178B2 (en) 1992-01-23
CA1328219C (en) 1994-04-05
DE3884044D1 (de) 1993-10-21
PT87381A (pt) 1989-05-31
ATE94390T1 (de) 1993-10-15
DD269784A5 (de) 1989-07-12
HUT46847A (en) 1988-12-28
DK169608B1 (da) 1994-12-27
HU199074B (en) 1990-01-29
FI882044L (fi) 1988-11-05
IL86211A0 (en) 1988-11-15
AU1555888A (en) 1988-11-10
EP0289977B1 (de) 1993-09-15
MX11339A (es) 1993-12-01
FI882044A7 (fi) 1988-11-05
KR960006059B1 (ko) 1996-05-08
EP0289977A1 (de) 1988-11-09
DK238888A (da) 1988-11-05
PH24895A (en) 1990-12-26
IE63081B1 (en) 1995-03-22
IL86211A (en) 1992-03-29
KR880013550A (ko) 1988-12-21
NO881933L (no) 1988-11-07
FI882044A0 (fi) 1988-05-02
PT87381B (pt) 1992-08-31
US5122543A (en) 1992-06-16

Similar Documents

Publication Publication Date Title
ES2043716T3 (es) Formas de administracion oral con liberacion retardada.
NO884467L (no) Analogifremgangsmaate for fremstilling av aminomethyloxooxazolidinyl-cykloalkylbenzenderivater.
FI872903A0 (fi) Kristalliskt hydrat av oral kefalosporin och dess komposition.
NO881398L (no) Fremgangsmaate for fremstilling av spinnflorstoff av filamentgarn.
ES2054379T3 (es) Formas farmaceuticas orales de pimobendano.
IT8567905A0 (it) Dispositivo osmotico per l erogazione di un farmaco ad una regione predeterminata della via gastrointesti nale particolarmente al colon
ES2192101T3 (es) Formas cristalinas de eto2c-ch2-(r)cgl-aze-pab-oh.
NO880261L (no) Fremgangsmaate for fremstilling av avermectin.
ITMI921022A1 (it) Procedimento per la preparazione di una forma liquida stabile di medicamenti contenenti beta-bloccanti con liberazione controllata del principio attivo per la somministrazione orale.
ES552145A0 (es) Procedimiento de fabricacion de una unidad de dosificacion para la administracion oral de cloruro potasico.
IT8422678A0 (it) Procedimento per la preparazione di una forma solida per uso orale abase di nifedipina con rilascio controllato del principio attivo.
DK223588D0 (da) Benzazepinderivater
DE3887790D1 (de) Lichtemittierende Halbleitervorrichtung.
CA1009739A (en) Semiconductor light source utilizing sic single crystal
IT8921614V0 (it) Scatoletta porta pillole con indicazione delle date di somministrazione.
ES2127600T3 (es) Procedimiento para la purificacion de n-vinilpirrolidona mediante cristalizacion.
IT1095750B (it) Procedimento per la fabbricazione di una carica luminosa
GB2062949B (en) Single filament semiconductor laser with large emitting area
FI881069L (fi) Foerfarande foer framstaellning av en transparent kapsel.
MY103367A (en) Oral forms of administration with delayed release
KR890005391U (ko) 발광 시계
CA959384A (en) Single crystal gem stones
IT8828919V0 (it) Monile luminoso
AU3113467A (en) Manufacturing filamentary silicon carbide crystals
BR8701363A (pt) Composto com potencialidade antiviral,antineoplasica e imunizante

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 289977

Country of ref document: ES